CN108478701A - 一种增强免疫力的含片 - Google Patents
一种增强免疫力的含片 Download PDFInfo
- Publication number
- CN108478701A CN108478701A CN201810312124.1A CN201810312124A CN108478701A CN 108478701 A CN108478701 A CN 108478701A CN 201810312124 A CN201810312124 A CN 201810312124A CN 108478701 A CN108478701 A CN 108478701A
- Authority
- CN
- China
- Prior art keywords
- weight
- ginseng
- parts
- radix ophiopogonis
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000036039 immunity Effects 0.000 title claims abstract description 24
- 239000007937 lozenge Substances 0.000 title claims abstract description 15
- 239000000284 extract Substances 0.000 claims abstract description 47
- 241000208340 Araliaceae Species 0.000 claims abstract description 38
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 38
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 38
- 235000008434 ginseng Nutrition 0.000 claims abstract description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 238000001035 drying Methods 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 9
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical class [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 235000019359 magnesium stearate Nutrition 0.000 claims description 4
- 239000011259 mixed solution Substances 0.000 claims description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 238000005469 granulation Methods 0.000 claims description 2
- 230000003179 granulation Effects 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 23
- 239000000463 material Substances 0.000 abstract description 14
- 239000002994 raw material Substances 0.000 abstract description 3
- 239000003826 tablet Substances 0.000 abstract description 3
- 208000033065 inborn errors of immunity Diseases 0.000 abstract description 2
- 230000000144 pharmacologic effect Effects 0.000 abstract description 2
- 208000028529 primary immunodeficiency disease Diseases 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 230000004089 microcirculation Effects 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 201000010099 disease Diseases 0.000 description 9
- 238000000605 extraction Methods 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 244000248557 Ophiopogon japonicus Species 0.000 description 6
- 235000013402 health food Nutrition 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 5
- 235000020710 ginseng extract Nutrition 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000002683 foot Anatomy 0.000 description 4
- 239000008862 fructus schizandrae, radix ginseng, radix ophiopogonis drug combination Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 238000005534 hematocrit Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 229930182490 saponin Natural products 0.000 description 3
- 150000007949 saponins Chemical class 0.000 description 3
- 235000017709 saponins Nutrition 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 102000003712 Complement factor B Human genes 0.000 description 2
- 108090000056 Complement factor B Proteins 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 240000006079 Schisandra chinensis Species 0.000 description 2
- 235000008422 Schisandra chinensis Nutrition 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 230000002929 anti-fatigue Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 108010084652 homeobox protein PITX1 Proteins 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- UGJAEDFOKNAMQD-DVQDXYAYSA-N (-)-Falcarinol Natural products CCCCCCC\C=C\CC#CC#C[C@@H](O)C=C UGJAEDFOKNAMQD-DVQDXYAYSA-N 0.000 description 1
- UGJAEDFOKNAMQD-MQNTZWLQSA-N (3S,9Z)-1,9-Heptadecadiene-4,6-diyn-3-ol Chemical compound CCCCCCC\C=C/CC#CC#C[C@@H](O)C=C UGJAEDFOKNAMQD-MQNTZWLQSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- UGJAEDFOKNAMQD-UHFFFAOYSA-N Falcarinol Natural products CCCCCCCC=CCC#CC#CC(O)C=C UGJAEDFOKNAMQD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 241001448424 Ophiopogon Species 0.000 description 1
- 229930195210 Ophiopogon Natural products 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- -1 drying Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- KKAHGGJBKUXDNQ-KRWDZBQOSA-N panaxynol Natural products CCCCCCCC=CC=CCC#C[C@@H](O)C=C KKAHGGJBKUXDNQ-KRWDZBQOSA-N 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 235000019353 potassium silicate Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000009877 shengmai Substances 0.000 description 1
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
- A23P10/28—Tabletting; Making food bars by compression of a dry powdered mixture
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Abstract
本发明涉及一种用于增强免疫力的含片,它由按重量份计的下述各原料组成:人参25~75份,麦冬100~200份。药材经水提、浓缩、干燥、粉碎、压片制成含片。本发明创新性地提取并调配人参、麦冬中的主要功能物质,通过调节人体微循环,从根本上改善免疫力低下的问题,具有显著增强免疫力的功效,并采用含片剂型,便于携带,方便不同人群服用。本发明所用药材药性温和,配方科学合理,对人体无毒副作用,经提取调配后,各药材的功效得到更好的发挥。
Description
技术领域
本发明涉及一种保健品,尤其涉及了一种增强免疫力的含片。
背景技术
人类对健康观念内涵的认识随着科技水平的发展而进一步深化,据世界卫生组织50多个国家医学专家研究发现,对各种疾病最好的治疗还是预防。目前各种医院的检查只能对已经产生的疾病进行诊断,一旦确认有病,也往往会因发现太晚而束手无策,即使通过现代医疗科技手段也难使病人恢复如初。《黄帝内经》有言:“上工治未病,不治已病,此之谓也”,治未病即采取相应的措施,防止疾病的发生发展,是我国传统医学的主要思想。任何疾病只要预防和保养在先,发病的机率就会很低,甚至可以完全化解和避免。预防疾病最重要的手段是增强机体免疫力。
而现有技术中的保健药品基本上对于免疫力的调节都靠“补”,即补充各种各样的维生素、氨基酸,服用后也有效果,但停用很短一段时间后,免疫力又会下降,没有达到从根本上改善人体脏器内部环境,使人体自身具备免疫力的功效。
发明内容
本发明的目的是针对现有技术的不足,提供一种能增强免疫力、无副作用的含片。
为了实现上述目的,本发明采用以下技术方案:
(1)取人参25-75重量份,麦冬100-200重量份。制取人参、麦冬混合提取液。
(2)将上述混合提取液于真空度-0.07~-0.09Mpa,温度50~70℃环境下减压浓缩至密度为1.10-1.15g/ml,得到混合浸膏。
(3)按重量份计,将上述混合浸膏与37-111重量份山梨糖醇混合,得到混合溶液。
(4)将上述混合溶液于真空度-0.07~-0.09Mpa,溶液温度35~55℃环境下微波干燥,得到混合干浸膏。
(5)将上述混合干浸膏粉碎,过14目筛网,与0.5-1.5重量份硬脂酸镁混合,得到颗粒。
(6)将上述颗粒压片,压片重量为1.5g/片,得到增强免疫力的含片。
进一步地,所述人参、麦冬混合提取液的制备方法如下:将50重量份的人参,150重量份的麦冬,用1600重量份的水煎煮2次,煎煮时间为1.5小时,滤出药液,药渣弃去,合并药液,即获得人参、麦冬混合提取液。
进一步地,所述步骤2中,密度为1.10g/ml。
进一步地,所述步骤3中,按重量份计,山梨糖醇用量为74份。
进一步地,所述步骤5中,按重量份计,硬脂酸镁用量为1份。
本发明的有益效果:
1.提高机体吞噬细胞的吞噬能力,NK细胞活性,提高机体免疫力。经动物试验证明,具有增强免疫力的保健功能。
本发明的适宜人群:免疫力低下者。
本发明的不适人群:少年儿童,孕妇,乳母。
本发明的食用方法及食用量:含服,每日2次,每次2片(1.5g/片)。
本发明的注意事项:本品不能代替药物。适宜人群外的人群不推荐食用本产品。
附图说明
图1为人参提取液提取流程图;
图2为麦冬提取液提取流程图。
具体实施方式
本发明由传统著名经典复方生脉饮(生脉散)减味而来,最早记载有生脉散的医学文献,经考证认为是金代张元素所著的《医学启源》。作者在书中曰:“麦门冬,气寒,味微苦甘,治肺中伏火,脉气欲绝,加五味子、人参二味,为生脉散,补肺中元气不足”。中医认为肺气不足会导致抗病能力低下,容易感染外邪,易于感冒,多有畏寒、流清涕之症,与现代医学的免疫力低下症一致。
原方中人参甘温,益元气,补肺气,生津液,是为君药。麦门冬甘寒养阴清热,润肺生津,用以为臣。人参、麦冬合用,则益气养阴之功益彰。五味子为佐药,敛肺止汗,生津止渴,与增强免疫力功能关系不大。本发明将生脉散减味,取人参、麦冬经水提、浓缩、干燥、粉碎和压片,利用现有技术添加辅料,制成含片服用。通过对提取工艺等进行优化,提高工艺提取率,提高各原料利用率,减少原料损失,本发明具有更好的药效;在保健领域产生意想不到的效果。
人参:本发明所涉及人参为五加科植物人参Panax ginseng C.A.Mey.的干燥根和根茎,于秋季采挖,洗净。栽培的俗称“园参”,播种在山林野生状态下自然生长的称“林下山参”。习称“籽海”。其味甘、微苦,性微温,归脾、肺、心、肾经,具有大补元气,复脉固脱,补脾益肺,生津养血,安神益智的功效。用于体虚欲脱,肢冷脉微,脾虚食少,肺虚喘咳,津伤口渴,内热消渴,气血亏虚,久病虚羸,惊悸失眠,阳痿宫冷。现代药理研究表明,人参具有诸多生理活性,如增强免疫力、调节心血管功能、抗疲劳、提高脑耐缺氧等作用。
麦冬:本发明所涉及麦冬为百合科植物麦冬Ophiopogon japonicas(L.f)KerGawl.的干燥块根。其味甘,微苦,性微寒。具有养阴生津,润肺清心的功效。用于肺燥干咳,阴虚痨嗽,喉痹咽痛,津伤口渴,内热消渴,心烦失眠,肠燥便秘。药理学研究显示,麦冬具有提高免疫力、对心血管具有保护作用,以及降低血糖、抗衰老、抗疲劳等诸多功效。
本发明的急性毒性试验:按《保健食品检验与评价技术规范》(2003年版) 进行急性毒性试验,大、小鼠雌雄两性别经口最大耐受量均大于20g/kg,为无毒级。
本发明的微核试验:按《保健食品检验与评价技术规范》(2003年版)进行微核试验,设受试物0.25、0.50、1.5ml/kg·bw 3个剂量组,对小鼠灌胃受试物微核试验结果为阴性。
本发明的精子畸形试验:按《保健食品检验与评价技术规范》(2003年版) 进行精子畸形试验,设受试物2.5、5.0、10.0g/kg·bw 3个剂量组,对雄性小鼠灌胃。受试物精子畸形试验结果为阴性。
本发明的Ames试验:按《保健食品检验与评价技术规范》(2003年版) 进行Ames试验,采用平板掺入法,测试剂量为5000、1000、200、40和8μg/ 皿。受试物Ames试验结果为阴性。
本发明的大鼠30天喂养试验:按《保健食品检验与评价技术规范》(2003 年版)进行大鼠30天喂养试验,实验三个剂量组分别相当于人推荐摄入量的25、 50、100倍。实验结果表明:本发明30天喂养试验各剂量指标均未见明显毒性反应。
本发明的增强免疫力功能动物试验:按卫生部《保健食品检验与评价技术规范》(2003版)进行,设受试物0.5、1.0和3.0g/kg三个剂量组,分别相当于人推荐摄入量的5、10和30倍。试验结果显示:本发明增强免疫力功能动物实验结果为阳性。
下面结合实施例对本发明作进一步说明。
实施例1
本实施例对本发明提取工艺进行了进一步研究:
(1)将按重量份计:人参50份,麦冬150份。以表2正交试验安排表进行提取,滤出药液,弃去药渣,得到人参、麦冬混合提取液。
(2)将上述混合提取液浓缩至密度1.10g/ml,得到浓缩提取液。
采用紫外分光光度法对各浓缩提取液中的总皂苷进行含量测定,以浓缩提取液总皂苷含量为考察指标,选用L9(34)表对煎煮次数(A)、煎煮时间(B)、加水量(C)三个因素进行正交试验,各因素均确定为三个水平,见表1,实验安排、实验结果及数据处理见表2,数据方差分析表见表3。
表1提取工艺实验因素水平表
表2提取工艺正交实验安排、结果及数据处理表
表3提取工艺方差分析表
方差分析结果表明:FA>F0.01(2,2),因素A的水平变化对实验结果有极显著性影响;F0.10(2,2)<FC<FB<F0.05(2,2),因素B、C的水平变化对实验结果有一定的影响。考虑到因素A总皂苷提取率的K2和K3相差不大,选择2次提取;因素B、C总皂苷提取率的K2和K3相差不大,从经济角度考虑,选择水量8倍;选择提取时间1.5小时。提取工艺的最佳方案为A2B2C2,即:药材加8倍量水煎煮2次,每次1.5小时,可获得较好的煎煮效果,原料中功效成分提取率最高,所得含片功效好。
实施例2
在对人参、麦冬混合提取工艺优化的基础上,本实施例对人参、麦冬配伍效果进行了研究:
(1)提取液制备
人参提取液:人参8倍量水煎煮2次,每次1.5小时,滤出药液,药渣弃去,得到麦冬提取液,具体如图1所示;
麦冬提取液:麦冬8倍量水煎煮2次,每次1.5小时,滤出药液,药渣弃去,得到麦冬提取液,具体如图2所示;
混合提取液:5重量份的人参,15重量份的麦冬混合后,用160重量份的水煎煮2次,煎煮时间为1.5小时,滤出药液,药渣弃去,合并药液,即获得人参、麦冬混合提取液。
(2)将上述3种提取液于真空度-0.07~-0.09Mpa,温度50~70℃环境下减压浓缩至密度1.10g/ml,分别得到人参浸膏,麦冬浸膏,人参、麦冬混合浸膏。
(4)将上述3种浸膏于于真空度-0.07~-0.09Mpa,浸膏温度35~55℃环境下微波干燥,经粉碎,得到人参提取物,麦冬提取物,人参、麦冬混合提取物。
另设阴性对照组,各组小鼠灌胃给样品,各组剂量分别为人参提取物 0.25g/kg,麦冬提取物0.75g/kg,混合提取物1.0g/kg,阴性对照组给予同等容积的去离子水,每天一次,连续31天。在实验结束前5天,每只鼠腹腔注射0.2ml 2%(v/v)压积绵羊红细胞悬液,进行免疫。免疫后4天,测量左后足跖部厚度,然后在测量部位皮下注射20%(v/v)压积绵羊红细胞悬液,每只鼠20μL(约1 ×108个压积绵羊红细胞),于注射后24h测定左后足跖部厚度,同一部位测量三次,取平均值。以左后足跖厚度差值(足跖肿胀度)来表示迟发型变态反应的程度,其数值越高表明小鼠免疫力越强,各组结果见表4。实验结果显示:本发明具有协同增强免疫力的功效,显著增加小鼠足跖肿胀度,即本发明功效效应大于人参、麦冬单效应之和。
表4本发明及人参提取物、麦冬提取物对小鼠足跖肿胀度的影响
从表中可以看出,本发明中人参、麦冬经处理后,具有协同增强免疫力的功能,其途径主要有两条:体外途径,人参、麦冬提取物富含多糖物质、皂苷类等多种活性物质,在混合提取浓缩干燥的过程中,分子间形成氢键,同时部分分子内糖苷键、酯键或酯键所连基团断裂,形成分子间共价键,使本发明体系稳定性提升并实现协同增强免疫力的功效;体内途径,在体内主要是通过各组分对不同靶点的作用,使相互作用增强。人参含有人参皂苷、人参多糖、人参醇等多种活性成分,对免疫系统、神经系统、心血管系统和内分泌系统等方面问题均有明显的疗效。麦冬含有皂苷、黄酮、氨基酸、多糖等多种活性成分,多与其他药材配合使用发挥功效,可增强大鼠肺组织SOD的活性,减少MDA 含量,抑制血浆促炎症因子IL-6、TNF-α和促纤维化细胞因子TGF-β1的释放。人参、麦冬可同时作用于人体抗炎、呼吸道相关网络中的多个靶点,君臣相佐,实现协同增强效应。因此,本发明通过联合人参、麦冬,在保证各自药用价值的前提下,产生了意想不到的技术效果。
实施例3
本实施例对本发明微波干燥工艺进行了进一步研究:
(1)将按重量份计:人参50份,麦冬150份,用1600重量份水煎煮2次,每次1.5h,滤出药液,弃去药渣,得到人参、麦冬混合提取液。
(2)将上述混合提取液于真空度-0.07~-0.09Mpa,温度50~70℃环境下,分别减压浓缩至表5所示密度,得到混合浸膏。
(3)将上述混合浸膏于真空度-0.07~-0.09Mpa,浸膏温度35~55℃条件下,分别微波干燥,得到混合干浸膏。
对各组浸膏干燥过程物料状态及干浸膏性状进行记录,所得结果见表5。实验结果显示,为密度1.10g/ml及1.15g/ml两个样品的干燥过程顺利,浸膏损失少。因此,本发明选择将浸膏浓缩至密度为1.10-1.15g/ml,其中考虑到减压浓缩功耗问题,优先选择将浸膏浓缩至密度为1.10g/ml。
表5不同密度浸膏微波干燥过程考察
以上实施例用来解释和说明本发明,并不用于限制本发明,所属领域的普通技术人员应当理解:依然可以对本发明的具体实施方式进行修改或者对部分技术特征进行等同替换,而不脱离本发明技术方案的精神,其均应涵盖在本发明请求保护的技术方案范围当中。
Claims (5)
1.一种增强免疫力的含片,其特征在于:通过以下方法得到:
(1)取人参25-75重量份,麦冬100-200重量份。制取人参、麦冬混合提取液。
(2)将上述混合提取液于真空度-0.07~-0.09Mpa,温度50~70℃环境下减压浓缩至密度为1.10-1.15g/ml,得到混合浸膏。
(3)按重量份计,将上述混合浸膏与37-111重量份山梨糖醇混合,得到混合溶液。
(4)将上述混合溶液于真空度-0.07~-0.09Mpa,溶液温度35~55℃环境下微波干燥,得到混合干浸膏。
(5)将上述混合干浸膏粉碎,过14目筛网,与0.5-1.5重量份硬脂酸镁混合,得到颗粒。
(6)将上述颗粒压片,压片重量为1.5g/片,得到增强免疫力的含片。
2.根据权利要求1所述的含片,其特征在于:所述人参、麦冬混合提取液的制备方法如下:将50重量份的人参,150重量份的麦冬,用1600重量份的水煎煮2次,煎煮时间为1.5小时,滤出药液,药渣弃去,合并两次煎煮的药液,即获得人参、麦冬混合提取液。
3.根据权利要求1所述的含片,其特征在于:所述步骤2中,密度为1.10g/ml。
4.根据权利要求1所述的含片,其特征在于:所述步骤3中,按重量份计,山梨糖醇用量为74重量份。
5.根据权利要求1所述的含片,其特征在于:所述步骤5中,按重量份计,硬脂酸镁用量为1份。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810312124.1A CN108478701A (zh) | 2018-04-09 | 2018-04-09 | 一种增强免疫力的含片 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810312124.1A CN108478701A (zh) | 2018-04-09 | 2018-04-09 | 一种增强免疫力的含片 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108478701A true CN108478701A (zh) | 2018-09-04 |
Family
ID=63315070
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810312124.1A Pending CN108478701A (zh) | 2018-04-09 | 2018-04-09 | 一种增强免疫力的含片 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108478701A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110025011A (zh) * | 2019-04-30 | 2019-07-19 | 浙江麦斯康莱医药有限公司 | 一种增强免疫力的麦冬人参含片 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104839723A (zh) * | 2015-06-03 | 2015-08-19 | 通化百泉保健食品有限公司 | 人参、麦冬复合保健含片及其制备方法 |
CN106389869A (zh) * | 2016-08-25 | 2017-02-15 | 苏州神元生物科技股份有限公司 | 一种增强免疫力的保健品 |
CN106983821A (zh) * | 2016-12-16 | 2017-07-28 | 云南腾药制药股份有限公司 | 一种增强免疫力的药物组合物及其制备方法、制剂与应用 |
-
2018
- 2018-04-09 CN CN201810312124.1A patent/CN108478701A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104839723A (zh) * | 2015-06-03 | 2015-08-19 | 通化百泉保健食品有限公司 | 人参、麦冬复合保健含片及其制备方法 |
CN106389869A (zh) * | 2016-08-25 | 2017-02-15 | 苏州神元生物科技股份有限公司 | 一种增强免疫力的保健品 |
CN106983821A (zh) * | 2016-12-16 | 2017-07-28 | 云南腾药制药股份有限公司 | 一种增强免疫力的药物组合物及其制备方法、制剂与应用 |
Non-Patent Citations (1)
Title |
---|
戴先芝: "麦冬人参提取物复合饮品的研制及其应用价值分析 ", 《食品研究与开发》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110025011A (zh) * | 2019-04-30 | 2019-07-19 | 浙江麦斯康莱医药有限公司 | 一种增强免疫力的麦冬人参含片 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103719498B (zh) | 一种提高免疫力的黄精保健茶及其制备方法 | |
CN102205107B (zh) | 一种治疗十二指肠溃疡的中药制剂及其制备方法 | |
CN101253903B (zh) | 一种具有减肥功能的保健食品及其制备方法 | |
CN101579120A (zh) | 一种具有减肥功能的营养食品及其制备方法 | |
CN108524814A (zh) | 一种用于降低血糖的中药组合物及其制备方法 | |
CN103719493B (zh) | 一种补脑益智的黄精保健茶及其制备方法 | |
CN102551046B (zh) | 一种天然减肥保健组合物及其应用 | |
CN101708306B (zh) | 一种治疗胃病的中药组合物及其制备方法 | |
CN104223297B (zh) | 一种延缓衰老的五味子保健口服液及其制备方法 | |
CN1558768A (zh) | 一种中药组合物及其制备方法 | |
CN104489172A (zh) | 一种提高免疫力的刺五加保健茶及其制备方法 | |
CN106692532A (zh) | 一种用于燃脂减肥的中药组合物及其贴剂和减肥套装 | |
CN108478701A (zh) | 一种增强免疫力的含片 | |
CN110025011A (zh) | 一种增强免疫力的麦冬人参含片 | |
CN102068520B (zh) | 一种治疗心脑血管疾病的中药组合物及其制备方法 | |
CN103181557A (zh) | 具有减肥功能的营养食品及其制备方法 | |
CN103393938B (zh) | 一种降血糖的中药组合物 | |
CN102327304B (zh) | 一种防治慢性高原病的药物及其制备方法 | |
CN114081171A (zh) | 一种具有辅助改善睡眠作用的功能性食品组合物 | |
CN105343808A (zh) | 一种具有减肥效果的中药组合物及其制备方法 | |
CN111407850A (zh) | 植物硒黄精片及其制备方法 | |
CN104258224A (zh) | 一种治疗肺肾阴虚型慢性支气管炎的五味子口服液及其制备方法 | |
CN110101813A (zh) | 一种治疗肾阳虚牡蛎组合物口服液制备方法及其应用 | |
CN104173745A (zh) | 一种滋补健身的蒙药 | |
CN112089783B (zh) | 中药组合物在制备预防或/和治疗肥胖的药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180904 |